MATRIX-2
Research type
Research Study
Full title
Monotherapy with a P2Y12 inhibitor followed by a direct-acting oral anticoagulant in patients with ATRial fIbrillation undergoing suprafleX Cruz coronary stent implantation (MATRIX-2)
IRAS ID
1009574
Contact name
Stephan Windecker
Contact email
Sponsor organisation
Insel Gruppe AG
Eudract number
2023-509717-36
Clinicaltrials.gov Identifier
Research summary
Patients with atrial fibrillation (AF) with indication for long-term oral anticoagulation undergoing undergone successful percutaneous coronary intervention (PCI) with one or more Supraflex Cruz stent implantation are routinely treated with a combination of antithrombotic medications. In this study we would like to investigate whether treatment with a single antithrombotic drug (“monotherapy strategy”) is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications (“standard-of-care strategy”). Participants will be randomly allocated to one of the two groups. The antithrombotic treatment regimen will then be prescribed according to group assignment. All drugs used in this study are approved and used in clinical practice. The duration of participation is 15
months. After completion of the study, the patient will receive antithrombotic therapy according to routine care.REC name
London - Brent Research Ethics Committee
REC reference
24/LO/0380
Date of REC Opinion
27 Jun 2024
REC opinion
Further Information Favourable Opinion